NCT00250861终止2 期
A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue
US Oncology Research42 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2005年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 110
- 试验地点
- 42
研究概览
简要总结
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:
- •Has previously undergone BEAC or BEAM autologus SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification - only B-cell lymphomas are permitted.
- •ECOG performance status 0-
- •Previously histological documented CD20 +NHL.
- •Is greater than 18 years of age.
- •Is 30-100 days from autologous peripheral blood stem cell transplant.
- •Must meet laboratory values (see protocol for values): Absolute neutrophils, hemoglobin and platelets.
- •Has a negative serum pregnancy test within 7 days prior to trial registration (only for female patients of childbearing potential).
- •If fertile, patient (male or female) has agreed to use physician-approved method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.
- •Has signed a Patient Informed Consent Form.
- •Has signed a Patient Authorization Form (HIPAA).
排除标准
- •Patients will be taken off treatment if any of the following occur:
- •ECOG PS >
- •A history of hypersensitivity to study drugs, or any component thereof, or anaphylactic history to murine protein.
- •Manifested cardiac complications during transplant, including arrthymias, congestive heart failure, angina, or myocardial infarct, or had a decreased LVEF to <45% prior to transplant
- •On systemic corticosteroids.
- •Diffusion capacity <60% (corrected) and has decreased 30% or more following transplant
- •Documented disease progression (See Section 10.1.6 for definition).
- •Active infection, and/or is known to be seropositive for hepatitis B, hepatitis C, or HIV
- •Pericardial effusion, pleural effusions, or ascites.
- •A history of very aggressive NHL, such as Burkitt's or atypical Burkitt's lymphoma
- •Receiving concurrent immunotherapy or rituximab therapy.
- •Previously received a solid organ transplant.
- •History of CNS involvement.
- •A serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
- •A history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.
- •A pregnant or nursing woman.
- •Unable to comply with requirements of study.
研究者
研究点 (42)
Loading locations...
相似试验
已完成
2 期
Study in Patients With Primary Breast Diffuse Large B-cell LymphomaLarge B Cell Diffuse LymphomaNCT01448096Chonbuk National University Hospital33
终止
2 期
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's LymphomaLymphoma, FollicularNCT00308087Genzyme, a Sanofi Company75
已完成
2 期
Rituximab in Combination With Outpatient Therapy for CD20+ LymphomaNon-Hodgkin's Lymphoma (CD20+)NCT00280878Bayside Health12
进行中（未招募）
2 期
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)Immune-related Adverse EventsAdvanced Solid TumorNCT04375228Columbia University7
已完成
2 期
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)LymphomaNCT01427114Konkuk University Medical Center33